Latest Breaking News On - Cipla agreement - Page 3 : comparemela.com

Pulmatrix Reports First Quarter 2021 Financial Results and Provides Business Update PUR1800 Phase 1b data anticipated in Q4 2021 Phase 1/ Phase 2 Study for PUR3100 in acute migraine treatment on-track for study start in Q1 2022 Cash runway extends beyond anticipated PUR1800 Ph1b and PUR3100 Ph1/Ph2 data milestones Pulmatrix seeks reaffirmation of 50/50 partnership from Cipla Technologies News provided by Share this article Share this article LEXINGTON, Mass., May 11, 2021 /PRNewswire/  Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today reports its first quarter 2021 financial results and provides a business update.

Stewartj tepperStephen silbersteinTed raadGeisel school of medicine at dartmouthPulmatrix incThomas jefferson universityCompany quarterly reports on formCipla technologiesRecent highlightsEnterprise innovationTypec meetingCommercialization agreementCipla agreementGeisel schoolChief executive officerPrivate securities litigation reform act